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ABSTRACT
Vaccination uptake in the Federation of Bosnia and Herzegovina (FBiH), in Bosnia and Herzegovina, is
suboptimal. This study aimed to (1) assess vaccination coverage, timeliness and drop-out for children born
in 2015 and 2016 and compare these with official administrative coverage estimates, (2) identify associations
between characteristics of children/caregivers and vaccination uptake. This was a cross-sectional study based
on patient files for children 12–23 months (n = 1800) and 24–35 months (n = 1800). Methods were adapted
from the World Health Organization cluster survey methodology. A two-stage stratified sampling procedure
was conducted in urban and rural strata. A structured paper-based formwas completed by a pediatrician/nurse
from randomly selected primary care centers and patient files. Estimates were based onweighted analysis with
a 95% confidence interval to account for the survey sampling design. Vaccination coveragewas consistent with
administrative coverage levels for BCG, DTP andMMR, and lower for HepB; all considerably lower than regional
targets. Children in urban areas had lower vaccination uptake. An assumption that anti-vaccination sentiment
prevails among caregivers was not confirmed; only 2% of children were not vaccinated at all, instead
challenges related to delays and drop-out. An assumption of caregiver concerns for the MMR vaccine was
confirmed with low uptake and delays. The FBiH has experienced vaccination schedule changes due to supply
issues; findings confirmed that sustainability in supply and schedule is high priority. These data are new and
provide important information for developing strategies to increase uptake.
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Introduction
Vaccination saves lives and prevents suffering for millions of
people every year,1 yet vaccination uptake at national and sub-
national levels across the World Health Organization (WHO)
European Region remains insufficient to stop the spread
of measles and other potentially life-threatening vaccine-
preventable diseases.2 The Federation of Bosnia and
Herzegovina (FBiH) is one of the two entities comprising Bosnia
and Herzegovina. Vaccination uptake in the FBiH has been
declining in recent years. According to administrative official
data, coverage for three doses of diphtheria-tetanus-pertussis
(DTP) and polio vaccine in children under 1 year declined from
86.2% to 72.3% during 2014–2018; while uptake of the first dose of
measles-mumps-rubella vaccine (MMR) declined from 89.1% to
68.4%,3 far from the 95% target set for both vaccines in the
European Vaccine Action Plan.4
A measles outbreak in the FBiH in 2014–2015 reached 5084
cases,5 and a current measles outbreak has seen 1332 cases
during 2019, with two related deaths of children under 1 year.
In its most recent report, the European Regional Certification
Commission for Poliomyelitis Eradication concluded that the
FBiH, due to its low population immunity, remains at high risk
of sustained polio outbreak following importation.6
There are no evidence-based data on the reasons for the
suboptimal vaccination uptake in the FBiH to inform the devel-
opment of tailored public health interventions. Some frequent
assumptions amongst key stakeholders include caregiver and
health worker vaccine hesitancy, misinformation, lack of trust,
health worker shortage, vaccine shortages, and immunization
schedule changes. Moreover, a comprehensive analysis has not
been done to describe vaccinated and unvaccinated population
groups in terms of characteristics such as birth order, residence,
education, age or community affiliations. Lastly, there are con-
cerns as regards the denominators used to calculate administra-
tive coverage due to inaccurate projections and thus the accuracy
of assessment. Administrative coverage is assessed by routine
reporting, starting from a health-care facility that performs
mandatory immunization, which is compiled by cantonal public
health institutes and passed to the Institute for Public Health of
FBiH. The number of doses administered to the target popula-
tion is divided by the total estimated number of people in the
target population.
CONTACT Sanjin Musa s.musa@zzjzfbih.ba Institute for Public Health of the Federation of Bosnia and Herzegovina, Maršala Tita 9, 71000 Sarajevo, Bosnia
and Herzegovina
HUMAN VACCINES & IMMUNOTHERAPEUTICS
2021, VOL. 17, NO. 1, 228–236
https://doi.org/10.1080/21645515.2020.1769396
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Given these challenges, the Institute for Public Health of the
FBiH decided to initiate a WHO Tailoring Immunization
Programmes (TIP) project to understand barriers and drivers
to childhood vaccination, to inform a strategy to increase vacci-
nation uptake.7–9 The TIP approach applies a people-centered
approach and draws on the COM-B (capability, opportunity,
motivation-behavior) system as a framework for changing
behavior.10 Three TIP formative research studies were con-
ducted in the FBiH from 2017 to 2019: two qualitative interview
studies with health workers and caregivers,11 to identify barriers
and drivers to positive vaccination behaviors, and the patient file
study presented in this paper. The aims of this study were to:
(1) assess the vaccination coverage, timeliness and drop-
out for children born in 2015 and 2016; and compare
these with official administrative coverage estimates;
(2) identify associations between the characteristics of
children/caregivers and vaccination uptake.
Methods
The childhood schedule for the FBiH is presented in Table 1.
Throughout the paper, we refer to vaccines by their abbrevia-
tion with a number to indicate the dose (e.g. DTP3 is the third
dose of diptheria-tetanus-pertussis-containing vaccine).
Study design and target population
This was a cross-sectional study, based on Primary Health
Care (PHC) facility patient files of children, which included
data about their caregivers.
We included two cohorts of children, born in 2015 (aged
24–35 months at the time of data analysis) and 2016 (aged
12–23 months at the time of data analysis) because of the change
in pertussis vaccine that occurred at this time (see Table 1 foot-
note). Children born in 2015 temporarily received a vaccine con-
taining whole-cell pertussis (not acellular) which has been the
issue of dispute in the past;12 thus, to minimize bias related to
this change in the schedule and the fact that it also affected HepB3
vaccine coverage, which is given simultaneously, we only reviewed
MMR uptake for these children, enabling us to review MMR1
uptake beyond 12 months of age. Children born in 2016 mainly
received acellular pertussis-containing vaccine; we, therefore,
included all vaccines except MMR1 in studying this cohort. The
inclusion of this cohort enabled us to review uptake in vaccina-
tions that are scheduled in the first 12 months of life.
Operational definitions
Fully vaccinated
● Child aged 12–23 months who received BCG, DTP3,
HepB3
● Child aged 24–35 months who received MMR1
Unvaccinated
● Child aged 12–23 months who had not received any of
BCG, DTP or HepB. To account for the fact that many
children receive their first doses of two vaccinations
(BCG and HepB1) in birth clinics, we also investigated
children who were unvaccinated except for those first
doses.
● Child aged 24–35 months who had not received MMR1.
Timeliness
● Child who had received vaccines on time according to
the childhood schedule for the FBiH
Drop-out
● Child who had received the first dose, but not the third
dose of DTP or HepB:
○ DTP drop-out: (DTP1 – DTP3/DTP1) * 100
○ HepB drop-out: (HepB1 – HepB3/HepB1) * 100
Sample size and sampling technique
The sampling frame and procedures were adapted from theWHO
Expanded Programme on Immunization (EPI) cluster survey.13
The sample size was calculated to allow us to estimate the FBiH
coverage with a confidence level no wider than 8%, when coverage
is between 50% and 70%, and with a design effect of 5.67.
Estimated total target participants: 2 (strata – urban/rural) x 159
(effective sample size) x 5.67 (design effect) = 1803. The final
sample size was rounded down to 1800 participants per age
group (900 for each urban and rural strata). The number of
patient files to check per cluster was 15, based on the number of
households a data collection team can visit in a day as well as the
total number of target respondents expected in an average size
cluster, assuming that all eligible respondents in those households
visited are interviewed. Since the sample size selection was done in
Table 1. Childhood immunization schedule in FBiH in 2016.
Vaccine Age
Bacillus Calmette Guérin (BCG) Neonates
Hepatitis B (HepB) Neonates, 1,
6 months
Diphtheria-tetanus-acellular pertussis (DTaP)1
Inactivated polio vaccine (IPV)
Haemophilus influenzae type b (Hib)
2, 4, 6 months
Measles-mumps-rubella (MMR) 12 months
Oral polio vaccine (OPV)-booster 18 months
Hib-booster (for children who received monovalent
vaccine)
18 months
DTaP-IPV booster 4 years
MMR 5 years
Diphtheria-tetanus (dT)
OPV-booster
13–14 years
Tetanus-booster 17–18 years
1From 2014 to 2016 there was a global shortage of combined vaccines with
acellular pertussis. In 2015, the tetravalent (DTaP-IPV + Hib) vaccine
(diphtheria, tetanus, acellular pertussis, and polio given simultaneously with
haemophilus influenzae type b) used in the primary series was replaced with
trivalent (DTwP + OPV + Hib) vaccine (diphtheria, tetanus, whole-cell pertussis,
given simultaneously with oral polio and haemophilus influenzae type b). Only
the first dose of the tetravalent vaccine remained in the schedule. By mid-
2016, pentavalent (DTaP-IPV-Hib) vaccine (diphtheria, tetanus, acellular per-
tussis, polio and haemophilus influenzae type b) was introduced into the
schedule for the first time. In 2017, the third dose of pentavalent vaccine
was moved from 6 to 10 months, and monovalent Hib-booster was removed
from the schedule, together with third OPV-booster and tetanus-booster.
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the PHC facility (not in the community), we defined a cluster as
a unit of 60 (4x15) patient files.
To categorize settlements as rural/urban, a 2013 census list
of FBiH municipalities by settlement type (rural/urban) was
used. Municipalities with at least 65% urban households were
classified as urban.14
Seventy-nine PHCs in the FBiH provide childhood vacci-
nation. The sizes of the birth cohorts were 19,358 in 2015 and
19,655 in 2016.15,16
A two-stage stratified sampling procedure was conducted in
each stratum (urban/rural). A sampling frame was created by
listing all the PHCs alongside the number of children in the
birth cohort from each PHC and then further segmenting the
PHCs into clusters (primary sampling units) comprising 60
patient files. PHCs with fewer than 60 patient files were combined
with neighboring PHCs to create a single cluster. Next, we ran-
domly selected 15 clusters in each stratum using Microsoft Excel
with the formula for randomization. Since the sampling units had
been split into sub-units (clusters), the weight template was
adapted. We computed a new measure of size by dividing the
sum of patient files in a PHC (or collection of PHCs) by the
resultant number of units created. All selected PHCs agreed to
participate and received a small fee for their participation.
Within the clusters selected in the first stage of the sampling
procedure, we randomly selected patient files for children born
in 2015 and 2016, using Microsoft Excel with the formula for
randomization. Patient files from a total of 3600 (1800 children
per age group) were reviewed during January 2018.
Normalized and post-stratified weights were computed.
The weights were normalized to the total number of selected
units; hence, each weight was multiplied by the sum of sam-
ples divided by the sum of weighted number of children (sum
of individual weights multiplied by the sample).
fi xð Þ ¼ w
xi  Sxi
P
j w
xi :Sxi
The normalized weights within a stratum were multiplied by
a factor that limits the sum of these weights to the proportionate
contribution of each strata in the sampling frame (Federation).
All estimates presented in the paper are based on weighted
analysis to account for the survey sampling design.
Data collection
A structured paper-based form was developed, pre-tested and
completed by a pediatrician/nurse from the selected PHCs. A sub-
sample was overseen by trained supervisors (MS, EP).Where data
were missing the pediatrician/nurse telephoned caregivers. With
no official classification of ethnicity, categorization of Roma/other
was based on the knowledge of the pediatrician/nurse.
Characteristics recorded in the form were:
● Child: gender, birth order, residence (urban/rural), com-
munity affiliation (Roma/other)
● Caregiver: education (none/low/medium/high), age,
number of children
Data were entered into MS Access 2013.
Data analysis
Descriptive statistics were generated to characterize the sam-
ple and weighted analyses to calculate coverage rates with
a 95% confidence interval (CI) for each vaccine/dose and for
the measurements of a fully vaccinated child. Bivariate and
multivariate analyses were done to explore the association
between each of the possible explanatory variables and the
outcome variable of fully vaccinated. Chi-square tests were
used to compare levels of uptake, and cox proportional hazard
regression for comparing timeliness. Analyses were conducted
using the R package srvyr.
Ethical approval
Ethical approval was secured from the Ethics Committee of
the Institute for Public Health of the FBiH. Only authorized
supervisors and pediatricians/nurses who already had access
to patient files reviewed these. Data were recorded anon-
ymously, no names were kept in the study database.
Results
Child and caregiver characteristics
The characteristics of the 1800 children and their caregivers in
both cohorts are presented in Table 2. Both weighted (by
population size) and non-weighted data are presented because
the urban and rural classification did not represent an equal
proportion of the population once weighted. For both age
groups just over half of the sample was boys; and the majority
was a first or second born child. Most mothers were aged
24–35 years and most fathers were 28–37 years old. In terms
of education, medium level (high school) was dominant
among mothers and fathers. Twenty children aged
12–23 months and 16 children aged 24–35 months were
identified as Roma.
Vaccination coverage
Vaccination coverage data by residence among children born
in 2015 and 2016 are presented in Table 3.
Coverage was lower for all vaccines for urban residences
compared to rural. The differences were most pronounced for
the three doses of DTP-containing vaccine, HepB3 and
MMR1. The vaccines administered at birth, BCG and HepB1
had the highest coverage (BCG: 98%, 95% CI 97–99%; HepB1:
98%, 95% CI 96–99%). Notably, HepB coverage decreased
with each dose, leading to coverage for the third dose of
64% (95% CI 57–71%). The same pattern was evident for
DTP-containing vaccine with coverage decreasing from 86%
(95% CI 81–90%) for first dose to 64% (95% CI 55–72%) at
third dose. Among children aged 24–35 months, MMR1 cov-
erage was 65% (95% CI 60–71%).
Just 2% (95% CI 1–3%) had received no vaccinations at all
(Table 3). To account for the fact that many children routi-
nely receive their first dose of vaccinations at birth, we also
looked at children who were unvaccinated except for BCG
and HepB1. A total of 8% (95% CI 4–11%) was unvaccinated
using this definition.
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For DTP, pentavalent vaccine was the most commonly
administered (coverage with 1st dose 66%, 2nd dose 68%,
3rd dose 59%), and trivalent vaccine was the least frequently
administered (coverage with 1st dose 0%, 2nd dose 4%. 3rd
dose 0%). The distribution of vaccines used for the
first, second and third dose is presented in Figure 1.
Patient file data versus official administrative coverage
estimates
Vaccination coverage data from the patient files were
compared with the data reported in the official annual
report (Figure 2). Coverage levels estimated in our study
were consistent with administrative levels for three of the
four vaccines (p-values for null hypothesis of no differ-
ence: BCG 0.93, DTP3 0.21, MMR1 0.63), but to
a lesser degree for HepB3 coverage, which was estimated
to be lower than the administrative level (64% vs.
72%, p = .04).
Timeliness
To assess timeliness, the age of children at the time of vacci-
nation was assessed for HepB, DTP, and MMR1.
The recommended timing for the three doses of HepB was
at birth, 1 and 6 months (or at least 6 months after the first
dose) and for DTP at 2, 4 and 6 months (Table 1). For
children who received all three doses of each vaccine, the
timing of vaccination by residence for each dose is presented
in Table 4. Mean age for all three doses was older than the
recommended age for both vaccines, with completion of each
vaccine at 8–9 months instead of the recommended 6 months.
Vaccination occurred later in urban than rural settings for
MMR1, and a slightly significant difference was found for
HepB1 (Table 4, Figures 3 and 4). Mean age for DTP1 was
3.8 months.
Drop out
The drop-out rate for HepB from first to third dose was 34%
(95% CI 27–41%). For DTP the rate was 26% (95% CI
19–33%).
Characteristics associated with full vaccination coverage
Table 5 presents the association between child and care-
giver characteristics in relation to full and no vaccination
coverage among children born in 2016, aged 12–23 months
Table 2. Characteristics of children and their caregivers by birth cohort 2016 and
2015 (unweighted and weighted), FBiH January 2018.
Characteristic
Children born in 2016 (aged
12–23 months)
Children born in 2015 (aged
24–35 months)
Unweighted
n
Weighted
n (95% CI)
Unweighted
n
Weighted
n (95% CI)
Total 1800 1800
(1658–1942)
1800 1800
(1658–1942)
Gender of child
Male 920 927 (821–1034) 898 894 (816–971)
Female 874 867 (792–943) 878 877 (795–960)
Birth order1
1 762 791 (647–934) 684 681 (541–821)
2 621 609 (564–654) 608 609 (513–705)
3 168 170 (111–229) 184 189 (139–239)
>3 45 47 (25–69) 45 56 (11–100)
Residence
Urban 900 674 (668–681) 900 674 (668–681)
Rural 900 1126
(983–1268)
900 1126
(983–1268)
Mother’s education2
None 5 5 (0–10) 8 9 (0–18)
Low 83 87 (53–120) 70 71 (40–103)
Medium 1044 1080
(938–1223)
991 1020
(859–1181)
High 591 547 (455–638) 570 529 (430–627)
Father’s education2
None 5 5 (0–10) 7 8 (0–15)
Low 56 57 (35–80) 36 39 (18–59)
Medium 1230 1265
(1123–1407)
1203 1219
(1038–1399)
High 440 400 (342–457) 404 375 (308–442)
Mother’s age (years)3
<24 200 207 (156–259) 115 116 (79–153)
24–29 526 548 (469–627) 462 490 (385–596)
30–35 674 665 (564–766) 690 677 (571–784)
>35 288 275 (214–337) 345 331 (265–396)
Father’s age (years)3
<28 228 236 (191–281) 144 146 (115–176)
28–32 642 645 (560–729) 599 599 (494–705)
33–37 528 536 (447–624) 580 577 (490–664)
>37 283 272 (219–325) 293 294 (221–367)
Community affiliation
Other 1780 1780
(1634–1926)
1784 1782
(1638–1925)
Roma 20 20 (5–35) 16 18 (7–30)
1Birth order was defined as 1 (first), 2 (second), 3 (third), >3 (forth or later child);
2Mother’s/Father’s education was defined as low (primary school), medium
(high school), high (university degree); 3Male/female age groups were chosen
to ensure even spread across groups. Average age of mothers was 31.7
(31.2–32.3) years and fathers 35.1 (34.6–35.6) years.
Table 3. Vaccination coverage by residence among children born in 2016 and
2015, FBiH January 2018.
Vaccine
Total
% (95% CI)
Urban
% (95% CI)
Rural
% (95% CI)
P-value
(urban/
rural)
BCG 98 (97–99) 97 (95–98) 99
(98–100)
0.059
DTP1-containing
vaccine
86 (81–90) 79 (73–84) 90 (84–96) 0.014
DTP2-containing
vaccine
78 (72–84) 70 (63–76) 83 (74–91) 0.029
DTP3-containing
vaccine
64 (55–72) 52 (44–59) 71 (59–83) 0.017
HepB1 98 (96–99) 96 (95–98) 99
(97–100)
0.13
HepB2 90 (86–94) 86 (82–90) 93 (87–98) 0.088
HepB3 64 (57–71) 51 (43–59) 72 (61–82) <0.01
MMR11 65 (60–71) 51 (44–57) 74 (66–82) <0.01
1Data for children aged 24–35 months only. Note. P-values for the difference
between urban and rural coverage were calculated using a chi-squared test.
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Figure 1. DTP vaccination coverage in 2016, by vaccines used, FBiH
January 2018.
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(excluding MMR). Just over half of the children (59%, 95%
CI 51–68%) were fully vaccinated. The odds of being fully
vaccinated were three times (95% CI 1.6–5.4) higher for
a child living in a rural area compared to an urban area.
Conversely, a child of Roma community affiliation was less
likely to be fully vaccinated than a non-Roma child
(although this is based on a small sample). None of the
other child or caregiver characteristics were strongly asso-
ciated with full vaccination coverage.
Table 6 presents the association between child and care-
giver characteristics in relation to full vaccination coverage for
MMR1 among children born in 2015, aged 24–35 months.
Two-thirds of the children were fully vaccinated (65%, 95% CI
60–71%). The odds of being vaccinated with MMR1 were 4.7
times (95% CI 2.6–8.2) higher for a child living in a rural area
compared to an urban area; and 1.4 times higher (95% CI
1.1–1.8) if the mother is older compared to younger
(>35 years to 30–35 years). None of the other child or care-
giver characteristics were strongly associated with MMR1
vaccination coverage.
98%
69% 72%
64%
0%
20%
40%
60%
80%
100%
BCG
(12−23 months)
DTP3
(12−23 months)
HepB3
(12−23 months)
MMR1
(24−35 months)
C
ov
er
ag
e
Administrative data
Study data
Figure 2. Vaccination coverage: patient file data compared with official administrative, FBiH January 20183 Note. Error bar represents one 95% CI. The coverage levels
estimated from our study data are shown in Table 3.
Table 4. Time of vaccination in months by residence among children born in
2016 and 2015, FBiH January 2018.
Vaccine
All
mean (95%
CI)
Urban
mean (95%
CI)
Rural
mean (95%
CI)
P-value
(urban/
rural)
BCG 0.30
(0.24–0.35)
0.31
(0.22–0.40)
0.29
(0.22–0.36)
0.23
DTP1-containing
vaccine
3.8 (3.3–4.3) 3.8 (3.5–4.1) 3.7 (3.0–4.5) 0.88
DTP2-containing
vaccine
6.3 (5.1–7.5) 5.9 (5.3–6.5) 6.5 (4.7–8.3) 0.96
DTP3-containing
vaccine
8.8 (8.3–9.4) 9.1 (8.5–9.7) 8.7 (8.0–9.4) 0.49
HepB1 0.33
(0.27–0.39)
0.40
(0.29–0.52)
0.29
(0.23–0.36)
0.044
HepB2 1.9 (1.7–2.1) 2 (1.8–2.2) 1.9 (1.6–2.1) 0.38
HepB3 8.8 (8.2–9.4) 9.1 (8.5–9.7) 8.6 (7.8–9.4) 0.43
MMR11 16 (15–16) 17 (16–18) 15 (14–16) <0.01
1Data for children aged 24–35 months only. Note. The recommended timing for
BCG was at birth, for the three doses of HepB were at birth, 1 and 6 months
(or at least 6 months after the first dose), for DTP at 2, 4 and 6 months, and for
MMR1 at 12 months. The results for children born in 2016 were assessed for
59% (51–68%) of the whole sample, and for children born in 2015 for 65%
(60–71%) of the whole sample. P-values for the difference between urban and
rural coverage were calculated using a cox proportional hazards model with
urban/rural status as sole predictor.
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Figure 3. Timing of vaccination by residence for DTP-containing vaccine, chil-
dren born in 2016 and aged 12–23 months, FBiH January 2018.
Note. Error bar represents one 95% CI. Dotted line represents the recommended
timing of vaccination.
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Figure 4. Timing of vaccination by residence for MMR1, children born in 2015
and aged 24–35 months, FBiH January 2018.
Note. Error bar represents one 95% CI. Dotted line represents the recommended
timing of vaccination.
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Discussion
This study assessed childhood vaccination coverage, timeli-
ness and drop-out in the FBiH and described the character-
istics of fully vaccinated children and their caregivers. These
data provide detailed insight, and alongside two qualitative
TIP studies conducted in parallel,11 are important information
for developing evidence-informed tailored interventions to
improve vaccination coverage in the FBiH.7–9
The study confirmed that vaccination coverage in the FBiH in
2016 was considerably lower than regional targets and coverage
in other central European countries;17,18 and that there are issues
related to delay and drop-out for a considerable proportion of
children. This increases the risk of outbreaks of vaccine-
preventable diseases with personal and financial implications
for individuals and health systems. Our findings also confirmed
the accuracy of the administrative data.3
Prior to conducting this study, there were a number of
assumptions in the FBiH about factors related to vaccination of
which some were confirmed, and others challenged by the study
findings. There was an assumption that anti-vaccination senti-
ment prevails among caregivers in the FBiH. This notion is
challenged by the high coverage for birth doses and vaccines
given at 1 and 2 months of age. Indeed, only 2% of the children
in this study were completely unvaccinated. Instead, the study
identified challenges related to the completion of the vaccination
schedule and timeliness. For all assessed vaccines, the study
confirmed considerable delays and drop-out. Insight from our
qualitative studies with caregivers (unpublished data) and health
workers;11 and a study in neighboring Serbia,19 offer potential
explanations for suboptimal vaccination for later doses (delay or
drop-out), including changes in immunization schedule, lack of
knowledge and/or information about the importance of com-
pleting the schedule, lack of encouragement from health workers
to return for vaccination; inefficient or a lack of reminders,
poorer doctor-patient relationship in urban comparing to rural
setting and overloaded pediatricians in urban settings, and com-
peting priorities for caregivers in urban settings.
Another assumption was that caregivers have particular
concerns about the MMR vaccine. Indeed, this was evident
from our interview studies with caregivers (unpublished) and
health workers.11 Anti-MMR vaccine information is increas-
ingly circulating in the Balkan countries (sharing similar
languages),20 and MMR vaccination rates in these countries
have declined more significantly than other vaccines.18 It is
known that some parents delay MMR vaccination due to
Table 5. Association between child and caregiver characteristics in relation to
BCG, DTP3, HepB3 (full vaccination) coverage among children born in 2016 and
aged 12–23 months, FBiH January 2018.
Characteristic
Fully
vaccinated
Crude odds ratio
(95% CI)
Adjusted1 odds ratio
(95% CI)
Total 59 (51–68)% n/a n/a
Gender of child
Male 58 (48–67)% Baseline Baseline
Female 61 (53–69)% 1.16 (0.94–1.43) 1.09 (0.89–1.33)
Birth order2
1 65 (56–74)% Baseline Baseline
2 57 (48–66)% 0.71 (0.57–0.88) 0.77 (0.60–0.98)
3 61 (45–77)% 0.83 (0.49–1.43) 0.87 (0.52–1.46)
>3 55 (32–78)% 0.66 (0.29–1.49) 0.80 (0.35–1.85)
Residence
Urban 47 (39–55)% Baseline Baseline
Rural 67 (55–79)% 2.26 (1.24–4.13) 2.96 (1.63–5.40)
Mother’s education3
None 0 (0–0)% 0.00 (0.00–0.00) 0.00 (0.00–0.00)
Low 49 (35–63)% 0.60 (0.37–0.97) 0.52 (0.24–1.11)
Medium 62 (52–72)% Baseline Baseline
High 61 (53–68)% 0.97 (0.70–1.34) 1.09 (0.73–1.63)
Father’s education3
None 0 (0–0)% 0.00 (0.00–0.00) 1.54 (0.36–6.51)
Low 54 (39–69)% 0.73 (0.45–1.19) 1.12 (0.47–2.65)
Medium 61 (52–70)% Baseline Baseline
High 60 (53–67)% 0.95 (0.72–1.25) 1.10 (0.82–1.47)
Mother’s age (years)4
<24 58 (43–72)% 0.94 (0.61–1.46) 0.77 (0.45–1.31)
24–29 62 (53–71)% 1.12 (0.88–1.44) 0.96 (0.71–1.29)
30–35 59 (51–68)% Baseline Baseline
>35 57 (46–67)% 0.89 (0.71–1.12) 0.95 (0.75–1.20)
Father’s age (years)4
<28 60 (47–73)% Baseline Baseline
28–32 62 (54–70)% 1.10 (0.82–1.47) 0.89 (0.61–1.31)
33–37 58 (49–68)% 0.94 (0.65–1.37) 0.76 (0.47–1.21)
>37 58 (47–69)% 0.93 (0.61–1.44) 0.86 (0.50–1.50)
Community affiliation
Other 60 (52–68)% Baseline Baseline
Roma 0 (0–0)% 0.00 (0.00–0.00) 0.00 (0.00–0.00)
1All explanatory variables included in the model. 2Birth order was defined as 1
(first), 2 (second), 3 (third), >3 (forth or later child); 3Mother’s/Father’s educa-
tion was defined as low (primary school), medium (high school), high (uni-
versity degree); 4Mother/father age groups were chosen to ensure even spread
across groups. Average age of mothers was 31.7 (31.2–32.3) years and fathers
35.1 (34.6–35.6) years.
Table 6. Association between child and caregiver characteristics in relation to
MMR1 (full vaccination) coverage, among children born in 2015 and aged
24–35 months, FBiH January 2018.
Characteristic
Fully MMR1
vaccinated
Crude odds ratio
(95% CI)
Adjusted1 odds ratio
(95% CI)
Total 65 (60–71)% n/a n/a
Gender of child
Male 64 (58–71)% Baseline Baseline
Female 67 (60–74)% 1.12 (0.89–1.40) 1.03 (0.78–1.36)
Birth order2
1 66 (59–73)% Baseline Baseline
2 66 (58–74)% 1.00 (0.79–1.27) 0.98 (0.75–1.30)
3 69 (62–76)% 1.13 (0.79–1.63) 0.85 (0.56–1.30)
>3 71 (57–85)% 1.25 (0.61–2.58) 0.69 (0.34–1.40)
Residence
Urban 51 (44–57)% Baseline Baseline
Rural 74 (66–82)% 2.81 (1.76–4.49) 4.65 (2.63–8.24)
Mother’s education3
None 54 (18–90)% 0.51 (0.13–1.94) 4.26 (0.39–46.02)
Low 67 (55–79)% 0.88 (0.52–1.47) 0.96 (0.44–2.06)
Medium 70 (64–76)% Baseline Baseline
High 61 (54–68)% 0.68 (0.53–0.86) 0.83 (0.64–1.07)
Father’s education3
None 36 (0–86)% 0.26 (0.03–1.92) 0.11 (0.01–1.51)
Low 66 (47–85)% 0.87 (0.42–1.84) 0.71 (0.28–1.77)
Medium 69 (64–74)% Baseline Baseline
High 61 (53–69)% 0.72 (0.57–0.91) 0.89 (0.65–1.22)
Mother’s age (years)4
<24 64 (55–74)% 1.02 (0.67–1.54) 0.70 (0.37–1.32)
24–29 70 (62–78)% 1.30 (0.95–1.77) 0.95 (0.60–1.51)
30–35 64 (58–70)% Baseline Baseline
>35 68 (62–74)% 1.19 (0.96–1.47) 1.44 (1.13–1.83)
Father’s age (years)4
<28 64 (53–74)% Baseline Baseline
28–32 65 (58–73)% 1.08 (0.72–1.62) 1.28 (0.70–2.34)
33–37 68 (62–74)% 1.23 (0.79–1.91) 1.49 (0.75–2.94)
>37 67 (60–74)% 1.15 (0.68–1.93) 1.13 (0.53–2.45)
Community affiliation
Other 66 (60–72)% Baseline Baseline
Roma 22 (0–45)% 0.14 (0.04–0.50) 0.25 (0.03–2.33)
1All explanatory variables included in the model. 2Birth order was defined as 1
(first), 2 (second), 3 (third), >3 (forth or later child); 3Mother’s/Father’s educa-
tion was defined as low (primary school), medium (high school), high (uni-
versity degree); 4Mother/father age groups were chosen to ensure even spread
across groups. Average age of mothers was 31.7 (31.2–32.3) years and fathers
35.1 (34.6–35.6) years.
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misperceived risks of potential side effects affecting walking
and speaking abilities.21,22 This current study confirmed that
one-third of eligible children had not received MMR vaccina-
tion, higher than for any other vaccines. Specifically, MMR1
vaccine compared to DTP1 vaccine was less accepted (65%
versus 86%) and more delayed (4 months versus 2 months).
Another explanation to the general pattern of low coverage at
12 months may be that at the time there were specific concerns
to the DTP vaccine. Asmentioned, whole-cell pertussis had been
temporarily reintroduced. Even if this did not affect the cohort
studied to great degree in terms of the vaccines which were
administered to them, the debate related to whole-cell pertussis
may have affected both health workers and caregivers. This
means that the delays related to DTP vaccine and low uptake
of DTP3 may be related to vaccine safety concerns as well.
The study confirmed a considerable delay for vaccines not
provided at birth or during initial months. In 2017 (the cohort
following our study), due to cost and supply issues, the immu-
nization schedule in the FBiH was changed with DTP3 being
postponed from 6 to 10months. Given the findings of this study,
such rescheduling may postpone DTP vaccination even further
into the child’s second year. In 2019, thanks to a multi-year
tender resulting in a decreased vaccine price and sustainable
supply, DTP doses were changed back to 2–4–6 months (includ-
ing a booster dose in the second year and a pre-school booster
dose). The findings of this study indicate that in order to achieve
early and durable protection against pertussis disease, the prim-
ing schedule with three DTP doses at 2–4–6 months or with
a shorter gap between second and third doses, is better opti-
mized compared to a schedule with two doses at 2–4months and
a booster at 10 months of age.
In terms of caregiver/child characteristics, the study clearly
showed that children living in urban areas have lower vacci-
nation coverage, evident for all vaccinations except BCG.
Differences in the timeliness of vaccination by residence
only applied for MMR1 where the delay was more frequent
for urban areas. International literature reports a positive
impact of maternal education on vaccination coverage,23
although conversely a popular assumption, especially with
MMR, is that highly educated parents are those most likely
to reject vaccination.24 Neither were supported by the find-
ings. We found no association with education, and with
complete vaccination coverage in urban areas lower than 50%.
Earlier data from the FBiH and wider Europe suggest low
vaccination coverage among Roma,25–27 and this was con-
firmed in this study, although this finding should be viewed
with caution given the small sample size. Given this finding,
additional explanations for suboptimal vaccination based on
evidence from other countries could again be speculated and
further explored for verification.
Finally, the use of digital technology for the vaccination
reporting would ensure accurate coverage estimates, and
should be considered for the future activities.
Strengths and limitations
The study method was unconventional, although based on an
accepted WHO methodology.13 Probability samples and
weighted statistical analyses were used at all stages of
sampling, thus reducing the potential for selection bias, and
allowing the calculation of meaningful confidence intervals
and confidence bounds.13
Regular surveys on national vaccination coverage provide
important information for public health officials and decision
makers, and public health practitioners and researchers are
encouraged to conduct them. Typically, evidence is usually
collected from home-based records (household surveys), as
well as from a vaccination history as recalled by the individual
or the child’s caregivers, which can be very expensive and
time-consuming. Our approach, using vaccination documen-
tation at the child’s health-care facility, was sufficient to con-
firm low coverage and provided additional valuable data
(which are not included in the administrative data), about
timeliness, and the characteristics of children and their care-
givers. This method could be adapted and used as a quick and
less expensive approach to cluster vaccination coverage sur-
vey, if there is documented evidence of vaccination in health
facilities. Feedback from participating pediatricians and
nurses was that the work was not a significant burden, and
they all provided the data within 1 week.
However, this method has several limitations: there might
be undocumented vaccination as children may have been
vaccinated at multiple health facilities, or in private clinics
that were not recorded in the patient file. Although we tried to
assess data on evidence for vaccination elsewhere in the files.
We found that 1% of children in both age groups had docu-
mented vaccination elsewhere. Also, data on caregivers’ char-
acteristics, for example, education and community affiliation
were inconsistently registered in files and required additional
data collection via phone by the pediatrician/nurse.
Due to vaccine supply issues, coverage was assessed for two
cohorts. Broader insights into vaccination coverage and
delayed vaccination would have allowed an assessment for
a broader age group, for example, up to 5 years; this was
not possible within the limitations of this project.
To minimize bias, categories were developed for each
question and data collection was supervised by appointed
supervisors. As part of quality control, analyses also included
internal consistency checks. As there is no official categoriza-
tion of specific population groups, the categorization of
“Roma” vs “other” had to be done based on the knowledge
of the person completing the data collection form. At the
same time, the Roma part of the sample was small. Findings
related to this population group should be interpreted with
care and inspire more research.
The findings of this study indicate that comprehensive
action, investment and prioritization from decision-makers
are immediately necessary for the FBiH to ensure the protec-
tion of the population against vaccine-preventable diseases. It
is important to ensure a stable supply of mandatory vaccines
to avoid vaccine shortages and consequential adjustment of
the immunization calendar; to educate health workers and
caregivers to improve knowledge related to safety concerns;
to improve urban vaccination settings in order to encourage
urban caregivers to bring children for vaccination; to support
Roma families to bring children for vaccination and finally,
and to digitalize the vaccination reporting system to ensure
accurate coverage estimates.
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Conclusions
The study confirmed the administrative coverage estimates
and that vaccination coverage for children born in 2015
(MMR1) and 2016 (BCG, HepB, DTP) is significantly below
the target immunization rates and is associated with consider-
able delays and drop-out. Very close to no children were not
vaccinated at all. The later doses have lower coverage than
doses given earlier. This is associated with high drop-out rates
and does not confirm a general anti-vaccination sentiment.
The study indicated that suboptimal vaccination coverage is
associated with: child living in urban area (low coverage and
delayed vaccination). Assessment of vaccination coverage of
children of caregivers of Roma origin indicated low coverage
and needs further exploration.
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